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Protocol
AbstrACt
Introduction The prevalence of postnatal depression 
(PND) is significant: reaching up to 20% in the general 
population. In mechanistic terms, the risk of PND lies in 
an interaction between a maternal psychophysiological 
vulnerability and a chronic environmental context of stress. 
On the one hand, repetition of stressor during pregnancy 
mimics a chronic stress model that is relevant to the study 
of the allostatic load and the adaptive mechanisms. On 
the other hand, vulnerability factors reflect a psychological 
profile mirroring mindfulness functioning (psychological 
quality that involves bringing one’s complete and non-
judgemental attention to the present experience on a 
moment-to-moment basis). This psychological resource 
is linked to protective and resilient psychic functioning. 
Thus, PND appears to be a relevant model for studying 
the mechanisms of chronic stress and vulnerability to 
psychopathologies. In this article, we present the protocol 
of an ongoing study (started in May 2017).
Methods and analysis The study is being carried out 
in five maternities and will involve 260 women. We aim 
to determine the predictive psychobiological factors for 
PND emergence and to provide a better insight into the 
mechanisms involved in chronic stress during pregnancy. 
We use a multidisciplinary approach that encompasses 
psychological resources and biophysiological and genetic 
profiles in order to detect relevant vulnerability biomarkers 
for chronic stress and the development of PND. To do so, 
each woman will be involved in the study from her first 
trimester of pregnancy until 12 months postdelivery.
Ethics and dissemination Ethics approval was obtained 
from the Ile de France III Ethics Committee, France (2016-
A00887-44). We aim to disseminate the findings through 
international conferences and international peer-reviewed 
journals.
trial registration number NCT03088319; Pre-results.
bACkground 
Mounting evidence shows that the perinatal 
period is a time of increased vulnerability for 
mood disturbances and the onset of psychi-
atric disorders.1 2 Among puerperal disorders, 
baby blues, postnatal depression (PND) and 
puerperal psychosis are the most frequent.1 
While baby blues appears to be a normal 
adaptive phenomenon, PND and puerperal 
psychosis are psychopathologies associated 
with maternal suffering and have negative 
consequences for the offspring and the family. 
PND, the most common childbearing compli-
cation, has a prevalence range of 10%–20% 
in Western countries.2 3 It is described as a 
non-psychotic depressive episode of mild to 
moderate severity, beginning in or extending 
into the first postnatal year.4 In the literature, 
two postpartum peaks have been identified: 
4 weeks and 6 months postdelivery.5 6 It is 
also important to note that PND is the first 
episode of depression in 6 out of 10 women.7 
There is no specific diagnostic classifica-
tion of PND. However, signs and symptoms 
are described in the Diagnostic and Statistical 
Manual of Mental Disorders, Fifth Edition 
(DSM-5) as being similar to those observed 
in major depressive episodes but with a peri-
partum onset specifier (either before or after 
childbirth).8–10 Therefore, the symptoms 
profile of PND is characterised by major 
negative effects that are associated with anhe-
donia (loss of interest in pleasurable activi-
ties) and aboulia (eg, behavioural disruption 
of sleep and appetite).7 Such symptoms 
strengths and limitations of this study
 ► Multidisciplinary approach to postpartum depres-
sion: genetic, physiological and psychosocial with 
three time points: 1, 6 and 12 months postdelivery.
 ► Identification of early biomarkers that will be good 
predictors of postpartum depression in order to set 
up prophylactic intervention.
 ► Given the way none pathological pregnancies are 
medically monitored in France (mostly outside of 
hospitals until the last 2 months of pregnancy), it 
may be difficult to include 260 participants in their 
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have to be observed for a minimum of 2 weeks and must 
represent a change from the previous functioning. PND 
has significant impact on the mother, her partner, the 
family, mother–infant interactions and on the long-term 
emotional and cognitive development of the baby. Besides 
being used for clinical diagnosis, the Edinburgh Postnatal 
Depression Scale (EPDS) is a screening tool widely used 
to detect and assess the severity of the depression.11
During pregnancy and postpartum periods, the 
maternal organism undergoes remarkable biological, 
physical, social and emotional changes. The most studied 
biological mechanisms are neuroendocrine abnor-
malities. The hormone withdrawal hypothesis of PND 
is supported by a number of human and non-human 
studies: the onset of depressive symptoms is linked to the 
sudden drop in the concentration of ovarian hormones 
(estradiol and progesterone).12 13 Hypothalamo–pitu-
itary–adrenal axis dysfunction also seems to be implicated 
in PND onset. Corticotropin-releasing hormone, adre-
nocorticotrophic hormone and cortisol levels increase 
during pregnancy and up to a few days postdelivery 
and then normalise within 12 weeks postchildbirth.14 15 
Conversely, the involvement of thyroid function in the 
mother’s major depressive episode remains unclear.13
Recent neurobiological studies have provided evidence 
for the involvement of the emotional neuronal circuit in 
this psychopathology.16 17 γ-Aminobutyric acid (GABA) is 
a potent inhibitory neurotransmitter that has been shown 
to be altered in PND (decreased inhibition), mainly due 
to altered receptor functionality.18 It is worth noting that 
GABA functioning is highly dependent on the oxidative 
status, which is a consequence of an imbalance between 
the production of free radicals and the failure of the 
antioxidant defence mechanisms. This dysregulation has 
been observed in psychopathological disorders such a 
depression.19
Furthermore, three stress-modulator neurotransmit-
ters seem to be directly or indirectly involved in PND: 
serotonin, dopamine and oxytocin.20 21 Chronic stress 
induces metabolic drift associated with reduced sero-
toninergic and dopaminergic transmission and is prob-
ably linked to inflammation as well as depression.20 The 
deleterious effects of stressful situations during the post-
partum period (up to 9 weeks) are buffered by endoge-
nous oxytocin, thus protecting women from developing 
depression.22
Other than its unique function during pregnancy, 
brain-derived neurotrophic factor (BDNF) is a key medi-
ator in neuronal plasticity and in mental disorders such 
as depression. The neurotrophin hypothesis argues that 
a stress-induced decrease of BDNF is linked with aber-
rant neurogenesis and subsequent major depression. This 
decreased BDNF activity in the brain is correlated with 
serum/plasma BDNF concentration. Low serum BDNF 
in late pregnancy is associated with higher depressive 
symptom23s.
In addition to hormonal and stress systems, immune 
dysregulation has also been hypothesised to contribute to 
PND. While proinflammatory cytokines decrease during 
pregnancy, anti-inflammatory cytokines increase. Within 
the first few hours after delivery, a sudden shift occurs 
that leads to the installation of a proinflammatory state.24 
The role of the immune function in the pathophysiology 
of depression is now clear: higher levels of proinflamma-
tory cytokines are associated with depressive episodes.25
Vulnerability to develop PND also arises from genetic 
polymorphism.26 Several lines of evidence suggest that 
(1) there is a specific genetic polymorphism of major 
depressive episodes occurring in the first year following 
birth and (2) clinical severity of the depressive episode 
is linked to specific genetic variations.27 Finally, epidemi-
ological studies have shown an association between gene 
polymorphisms involved in stress regulation and mood 
disorders/PND.27 28
Socioeconomic and psychological factors are also of 
great importance in the risk of developing PND. Social 
context can be either protective (ie, social support) or 
deleterious (ie, low income) and thus responsible of stress 
levels during pregnancy.29 Epidemiological studies show 
a link between maternal anxiety and mood symptoms 
during pregnancy and PND.30 Personality aspects (such 
as neuroticism and low self-esteem),31 as well as coping 
strategies,32 appear to be key factors in PND vulnerability.
Mindfulness is a psychological quality that involves 
bringing one’s complete attention to the present expe-
rience on a moment-to-moment basis and in a particular 
way: in the present moment and non-judgementally.33 
This ability is associated with low neuroticism, high 
self-esteem and efficient coping.34 In both healthy indi-
viduals and people with medical conditions, mindfulness 
allows a better regulation of physiological and psycho-
logical stress.35 36 To the best of our knowledge, mindful-
ness and major maternal depressive episodes have never 
been studied. Since this ability is highly beneficial in 
preventing the development and relapse of depression,37 
one might expect PND to be less frequent in mindful 
women.
In light of the gathered evidence (biological, genetic 
and psychosocial), a hypothesis can be made: the risk 
of emergence of PND relies on an interaction between 
a maternal psychobiological vulnerability and a chronic 
environmental context of stress. PND appears as a rele-
vant model for studying the mechanisms of chronic stress 
and vulnerability to psychological pathologies.
On the one hand, daily stressors (such as social, familial 
or work stress) during pregnancy correspond to a natural 
chronic stress model of several months and thus allows 
the study of the biological cost of responses to repeated 
stresses and the adaptive mechanisms leading to the func-
tional drift to psychic dysfunction.
On the other hand, isolated vulnerability factors charac-
terise a mirroring psychological profile of a mindfulness type 
of functioning. This psychological resource has been associ-
ated with resistant or even resilient psychic functioning.
This study aims to follow a cohort of pregnant women 
from the first trimester of pregnancy to 12 months after 
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delivery to determine the predictive psychobiological 
factors of the emergence of PND.
objectives
The primary aim of the study is to determine the predic-
tive psychobiological factors for the emergence of PND. It 
involves a multidisciplinary approach that will encompass 
psychological resources and biophysiological and genetic 
profiles.
The secondary aims are to provide a better insight into 
the mechanisms involved in chronic stress during preg-
nancy. We will follow changes in biological, physiological 
and psychological parameters in order to detect relevant 
vulnerability biomarkers for chronic stress and the devel-
opment of PND.
Finally, two exploratory objectives will aim to assess the 
relevance of neurotrophic factors and genetic polymor-
phisms in the risk of developing PND.
MEthods
Patient and public involvement
Patients and public were not involved in the development 
of the research question or in the design of the study. 
Dissemination of the general results (no personal data) 
would be made on demand.
trial design and setting
We aim to undertake a multicentric prospective longitu-
dinal study. The study will take place in hospitals where 
participants can be included in their first trimester of 
pregnancy. So far, five hospitals have been involved: Pôle 
HFME, CHR Mercy, Metz – Maternité GH Diaconesses 
Croix St Simon, Paris – Centre Aliénor d’Aquitaine, CHU 
Pellegrin, Bordeaux and Unité FIV, Pôle gynécologie, 
obstétrique et reproduction, CHU Estaing, Clermont-Fer-
rand – Centre Hospitalier Sud Francilien, CHSF Evry.
Eligibility criteria
The women involved in the study will have to meet the 
following requirements:
Inclusion criteria
 ► Before 17 weeks of gestation.
 ► Pregnancy monitoring planned within one of the 
facilities involved in the project.
 ► Full fluent in French.
 ► Women over 18 years old.
 ► Covered by the French National Health Service.
Non-inclusion criteria
 ► Pathological pregnancy requiring increased medical 
monitoring.
 ► Multiple pregnancy.
 ► Ongoing pathologies at the time of inclusion: (1) 
immune or endocrine conditions; (2) any psycholog-
ical disorders (PTSD, depression or anxiety disorders 
and so on); or (3) neurological pathologies such as 
multiple sclerosis.
 ► Hormonal or psychotropic drug therapies.
End of the trial
During the study, if a participant meets one the following 
criteria, her participation will be discontinued:
 ► Withdrawal of consent.
 ► Occurrence of a non-inclusion criteria.
 ► Medical condition interfering with the protocol.
 ► Death or ‘lost-to-follow-up’.
 ► If a pregnancy becomes ‘pathological’, the partici-
pant will have the choice to continue or to stop her 
involvement in the project; the pathological event will 
be recorded in the case report form.
Recruitment started in April 2017 and will last 30 
months.
Adverse events and other unintended effects of the 
study will be reported in compliance with the French 
public health code.
Intervention: participant timeline
This study aims to follow pregnant women, civilian or 
military, from the first trimester of pregnancy up to 12 
months postbirth. As shown in figure 1, each woman will 
have to attend 10 visits: one visit within the first 14 weeks 
of pregnancy (inclusion visit (VI)), one visit every month 
during the other two trimesters of pregnancy (VP5 to 
VP9), one visit within the 48 hours of the birth (VB1) and 
three visits 2, 6 and 12 months after delivery (VB2, VB3 
and VB4, respectively).
The last three VB visits may be performed remotely. 
The follow-up includes genetic, biological, physiolog-
ical and/or psychological parameters. During the inclu-
sion visit, participants will receive information on the 
protocol, provided by competent person (medical doctor 
or midwife), sign the consent forms (one to participate in 
the study and one for the genetic analysis) and undergo a 
complete assessment, which includes psychological ques-
tionnaires, measurement of heart rate variability (HRV), 
and the collection of genetic, hair and blood samples. For 
the remaining two trimesters of pregnancy, psychological 
assessments and HRV measurements will be performed 
monthly, whereas blood sampling will only be done on 
VP6 and VP8. Within 48 hours of the delivery (VB1), 
blood and hair will be collected and questionnaires will be 
completed. The last three visits (VB2, VB3 and VB4) will 
only require the completion of the psychological ques-
tionnaires. Details of the psychological questionnaires 
and genetic analyses can be found in tables 1 and 2.
outcomes
The primary outcome of the study is the identification of 
predictive psychobiological risks factors for development 
of PND. PND will be assessed using the EPDS (with a 
screening cut-off >11).38 The EPDS is a 10-item self-report 
questionnaire assessing the symptoms of depression and 
anxiety. The factors assessed will include psychopatho-
logical and positive psychological aspects (see table 1 for 
detail of the questionnaires used).
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Figure 1 Synopsis of study design. (Top) Study timeline for each participant and (bottom) details of visit requirements. Each 
participant will have to attend 10 visits from their first trimester of pregnancy until 12 months postdelivery. VB, postbirth 
visits 48 hours, 2, 6 and 12 months postdelivery; VI: inclusion visit; VP, pregnancy visits from the 5th month to the 9th month of 
pregnancy.
Table 1 Summary of psychological and psychopathological questionnaires
Pregnancy Postbirth
Inclusion visit VP5 to VP9 VB1
VB2, VB3 and 
VB4
Pathological Symptom Checklist 90 x
State-Trait Anxiety Inventory x x (state) x (state)
Edinburgh Postnatal Depression Scale x x x
PTSD Checklist for DMS-5 x x
Profile of Mood Scale x x
Questionnaire to detect the risk of PND x x
Traumatic Event Scale x
Peritraumatic Dissociative Experiences 
Questionnaire
x
Traumatic Delivery Impact x
Maternal Self-Esteem x
Personality Temperament and Character Inventory x
Positive psychology Freiburg Mindfulness Inventory x
Warwick Edinburgh Mental Well-Being 
Scale
x
Prenatal Antenatal Inventory x x
Multidimensional Scale of Perceived 
Social Support
x x x x
Labour Agentry Scale x
VAS Professional stress x x
Personal stress x x
Sleep quality x x
Delivery Anticipatory Stress x x
Medical staff support during delivery x
Three psychological aspects are studied: personality, psychopathology and positive psychology. VAS aim to determine stress 
level.
DSM, Diagnostic and Statistical Manual of Mental Disorders; PND, postnatal depression; VAS, visual analogue  scale, VP 
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The secondary outcomes will contribute to the under-
standing of the stress mechanisms involved throughout 
the pregnancy:
i. Biological stress: GABA, thiobarbituric acid reactive 
substances (byproducts of lipid peroxydation), in-
flammatory cytokines, cortisol and the endobiogenic 
index.
ii. Physiological stress: measurement of HRV to de-
termine the activation of the autonomous nervous 
system.
iii. Psychological stress: perceived stress, social support 
and life quality.
The exploratory objectives will include the study of 
genetic polymorphisms linked to stress vulnerability 
(see table 2) and central functioning (BDNF and eight 
iso-prostaglandine F2a).
Material
Heart rate variability
HRV will be measured in order to assess the reac-
tivity of the autonomic nervous system. HRV will be 
recorded on a monthly basis using the CODESNA 
Physioner system. Heart rate, HRV components (high 
frequency (HF); low frequency (LF) and LF/HF ratio) 
will be examined as described by the Task Force.39 The 
measurement of HRV will be conducted in sitting and 
resting participant.
Questionnaires
The psychological assessment will encompass patho-
logical, personality and positive psychology aspects 
(for details, see table 1). Stress levels will be assessed 
using visual analogue scales. All the selected ques-
tionnaires are self-reporting questionnaires that have 
been validated in French and have demonstrated good 
psychometric properties. Ideally, all of these assess-
ments should be performed before any potentially 
stressful exam.
Blood, hair and genetic samples
All sampling will be conducted according to the stan-
dard operating procedures described by the sponsor 
and in accordance with local procedures. Hair, blood 
and genetic samples will be conditioned locally and 
stored at room temperature or at −20°C. All biolog-
ical materials will then be transferred for analysis to 
the laboratories (Biolabs or IRBA) by a professional 
delivery company . Blood samples will be used for 
the analysis of all the biological parameters, except 
cortisol, which will be assessed using hair.
statistics
Number of participants needed
Several lines of evidence have been used in order to 
determine the number of participants required.
1. Maternity activities: over 2500 births/year in the CHU 
Pellegrin and CHR Mercy, 1000 births/year in GH 
Diaconesses Croix St Simon and up to 200 medical-
ly assisted procreations in the CHU Estaing.
2. In the general population, prevalence of PND is 20%; 
therefore, if we include 260 subjects, 52 should be 
diagnosed with PND. Among these, 5% of the moth-
ers-to-be might discontinue the Stress protection for 
postnatal dEpREssioN prevention (SERENE) project 
before completion, so 42 participants with PND should 
remain. 
3. The psychometric tools used in the general population 
show that it is possible to distinguish between mindful 
Table 2 Summary of gene polymorphism analysis
Genes Function
BDNF
Brain-derived
neurotrophic factor
Neuronal growth factor linked to the development of 
psychopathologies (such as anxiety)
COMT Catechol-O-methyltransferase Involved in stress regulation (catecholamine)
NPY Neuropeptide Y Role in stress response, circadian rhythms and cardiovascular 
functions
NR3C1 Glucocorticoid receptor (GR) GR transcription factor
NR3C2 Mineralocorticoid receptor (MR) MR transcription factor
FKBP5 FK506 binding protein 5 Gene encoding cochaperone protein essential in GR signalling
SLC6A4 Sodium-dependent serotonin transporter Serotonin transporter gene
NPS Neuropeptide S Peptide involves in anxiety, food intake and sleep quality
NPSR1 Neuropeptide S receptor Receptor involves in anxiety, food intake and sleep quality
CRHR1 Corticotropin-releasing hormone receptor Involved in HPA axis regulation
DRD2 Dopamine receptor D2 G protein-coupled receptor
OXT Oxytocin/neurophysin I prepropeptide Role in cognition, maternal behaviour and cardiovascular functions
HMNCN1 Hemicentin-1 Protein involved in postpartum depression
The chosen single nucleotid polymorphism (SNP) aim to characterise vulnerability and severity of PND as well as stress 
sensitivity.
HPA, hypothalamo–pituitary–adrenal axis; PND, postnatal depression.
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and less mindful subjects within a sample of 20 subjects 
(Friburg Mindful Inventory cut-off score above 37). 
However, since mindfulness has never been assessed in 
pregnant women, no threshold between high and low 
mindfulness has been determined in such a popula-
tion.
4. Given the prevalence of stress in the general popu-
lation (30%), we expect to get 78 stressed subjects 
among the 260 participants included.
Therefore, we aim to recruit 260 participants, which 
represents less than 5% of the total pregnancies 
followed in the five centres in 1 year.
General design
Central tendency and the variability of the continuous 
variables will be described depending on whether or 
not they follow a normal distribution (using the Shap-
iro-Wilk test). If there is normal distribution, data will 
be summarised using means and SD, if not medians 
and ranges will be used. VAS variables will be analysed 
like ordinal data and described as above.
If required, class gathering into categorical variables 
will be performed. These variables will be described as 
absolute values and percentages.
Any variable with more than 10% missing data will 
not be analysed.
Analyses for the primary outcome
A cut-off score of 11 in the EPDS has been shown to be a 
sensitive and specific threshold for PND emergence. We 
will use multivariate logistic regression in order to detect 
predictive factors of PND emergence. Threshold sensi-
tivity in terms of sensitivity, specificity and predictive value 
will be performed using receiver operating characteristic 
analysis.
A two-step approach will be conducted. First, a theme 
reasoned mixed approach will be undertaken to eval-
uate the weight of each biomarker for PND risk. Four 
themes have been identified: (1) biography (full-term 
delivery and life events), (2) psychological resources, 
(3) biophysiological profiles and (4) genetics. A final 
model will then be determined using mixed logistic 
regression from the variables selected from the previous 
step.
Analyses for the secondary and exploratory outcomes
The role of each biomarker and psychological factor in 
PND will be compared between the two groups (PND 
and non-PND) using an analysis of variance factorial 
analysis. Life events during the pregnancy and the 
subject’s status (civilian, military or spouse of force 
personnel) will be considered. PND risk factors linked 
to difficult labour/delivery will be controlled.
Finally, a composite index taking all the relevant 
biomarkers together will be computed in order to have 
a single predictive variable for the risk of developing 
PND.
data collection and management
In order to ensure the quality of the data collected 
and to promote participant retention, an assistant will 
be in charge of conducting the project according to 
the protocol in each centre involved in the SERENE 
project. The study will be implemented and conducted 
by the clinical research assistant (CRA) coordinator of 
the Direction Centrale du Service de Santé des Armées 
(DCSSA) in accordance with to the monitoring plan. 
As much as possible, the CRA will ensure the quality of 
the collected data in each centre in order to minimise 
missing data.
Personal information, data entry, coding, security 
and storage are processed in compliance with the Data 
Processing, Data Files and Individual Liberties Act of 6 
January 1978.
Ethics and dissemination
The study poses little to no risk to the participants or 
their infants and does not interfere with the typical 
care received during pregnancy. This protocol will 
certainly detect some episodes of depression; such 
an event will be communicated to the caregivers or 
the participant herself in order to set up an adequate 
alternative care. Study results will be disseminated at 
national and international conferences and in peer-re-
viewed journals. The trial findings could also be made 
available to participants collectively. Any modifications 
of the protocol will be submitted to the competent 
authorities (if required) and communicated to every 
relevant party as specified by the French public health 
code.
All the data will remain the property of the sponsor. 
The final data report will be written by all the asso-
ciated scientific investigators (as defined in the 
protocol).
dIsCussIon
Potential limitations
We have identified two potential limitations:
i. Given the way none pathological pregnancies are 
medically monitored in France (mostly outside of 
hospitals until the last 2 months of pregnancy), it may 
be difficult to include 260 participants in their first 
trimester. For this reason, a ‘recruiting network’ was 
initiated in each maternity (ie, involvement of doc-
tors doing first trimester ultrasounds and network of 
independent midwives), which should help to reach 
this goal.
ii. For the study, participants need to attend 10 visits, 
which might seem demanding. Furthermore, the 
last three visits are important since the diagnosis of 
PND may be made at this time. So, to make sure that 
participants will complete the protocol, one person 
(other than the investigators) is in charge of the par-
ticipants’ follow-up in each maternity.
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trial status
The study is currently recruiting participants.
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